Royalty Pharma: Solid Operational Performance [Seeking Alpha]
Royalty Pharma plc - Class A Ordinary Shares (RPRX)
US:NASDAQ Investor Relations:
ir.reprosrx.com/investor-relations
Company Research
Source: Seeking Alpha
The company increased its dividend per share by 5% and reported adjusted cash receipts that exceeded internal expectations. Royalty Pharma provided new full-year 2024 guidance. Still no news on Vertex. That said, we believe the company offers an attractive entry point. Royalty Pharma plc ( NASDAQ: RPRX ) released its Q4 results yesterday. The company delivered outstanding results in 2023 and deployed capital in key value-enhancing transactions for a total consideration of $4 billion. Royalty Pharma is one of the few companies rated as a Strong Buy. As a reminder, at September-end, we started a long position backed by 1) its unique diversified portfolio, 2) lower execution risks compared to traditional pharma players, 3) a compelling valuation versus royalties companies, and 4) a sound management team with supportive capital allocation priorities. For a complete overview, here is our initiation of coverage and the Q3 results analysis. Before commenting on the Q4 results, it
Show less
Read more
Impact Snapshot
Event Time:
RPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RPRX alerts
High impacting Royalty Pharma plc - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
RPRX
News
- Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21 [Yahoo! Finance]Yahoo! Finance
- Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024GlobeNewswire
- Royalty Pharma Declares Second Quarter 2024 DividendGlobeNewswire
- Royalty Pharma plc (NASDAQ: RPRX) had its price target lowered by analysts at Bank of America Co. from $40.00 to $38.00. They now have a "buy" rating on the stock.MarketBeat
- Royalty Pharma plc (NASDAQ: RPRX) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
RPRX
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form DEF
- RPRX's page on the SEC website